Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target refers to a specific genomic DNA sequence recognized and cleaved by the engineered Cas12f1 (eCas12f1) system, a miniature CRISPR effector derived from Type V-F CRISPR-Cas systems (Kim et al., 2022, Nature Biotechnology). eCas12f1 is approximately one-third the size of Cas9, making it highly suitable for delivery using size-constrained vehicles like adeno-associated virus (AAV) for human gene therapy (Xu et al., 2021, Nature Communications). The target sequence must be located immediately adjacent to a T-rich protospacer adjacent motif (PAM), typically 5'-TTTR-3', which is essential for the initial binding and DNA unwinding by the eCas12f1-sgRNA complex (Karvelis et al., 2020, Nucleic Acids Research). Upon successful hybridization of the sgRNA spacer with the complementary DNA strand, the enzyme's RuvC nuclease domain generates a double-strand break (DSB). This targeted cleavage allows for precise genome modifications, including gene disruption via non-homologous end joining or gene correction via homology-directed repair, to treat various genetic disorders and cancers. The interaction between the eCas12f1-sgRNA complex and this DNA target is the fundamental mechanism for its application as a programmable genome-editing tool. Specificity is maintained through the complementarity between the sgRNA spacer and the target DNA, though potential off-target effects remain a primary safety concern in clinical applications.
Site-specific DNA cleavage mediated by the RuvC nuclease domain of eCas12f1 following sgRNA-guided recognition of a T-rich protospacer adjacent motif (PAM) and hybridization with the complementary genomic DNA sequence.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Genomic DNA target sequence (eCas12f1-specific) (DNA target).